Overview
Toru Nanmoku practices in Tsukuba, Japan. Mr. Nanmoku is rated as an Experienced expert by MediFind in the treatment of Peripheral Neuropathy. His top areas of expertise are Acute Monoblastic Leukemia (AmoL), Lymphofollicular Hyperplasia, Angioimmunoblastic T-cell Lymphoma, and Non-Hodgkin Lymphoma.
His clinical research consists of co-authoring 29 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Peripheral Neuropathy.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Acute Monoblastic Leukemia (AmoL)Mr. Nanmoku isAdvanced. Learn about Acute Monoblastic Leukemia (AmoL).
- Lymphofollicular HyperplasiaMr. Nanmoku isAdvanced. Learn about Lymphofollicular Hyperplasia.
- Experienced
- Acute Lymphoblastic Leukemia (ALL)Mr. Nanmoku isExperienced. Learn about Acute Lymphoblastic Leukemia (ALL).
- Acute Megakaryoblastic LeukemiaMr. Nanmoku isExperienced. Learn about Acute Megakaryoblastic Leukemia.
- Acute Myeloid Leukemia (AML)Mr. Nanmoku isExperienced. Learn about Acute Myeloid Leukemia (AML).
- Angioimmunoblastic T-cell LymphomaMr. Nanmoku isExperienced. Learn about Angioimmunoblastic T-cell Lymphoma.
- B-Cell LymphomaMr. Nanmoku isExperienced. Learn about B-Cell Lymphoma.
- Cardiac TamponadeMr. Nanmoku isExperienced. Learn about Cardiac Tamponade.